Skip to main content
. 2016 Jul 20;43(4):256–267. doi: 10.1159/000447458

Table 2.

Selected recent studies using preconditioned MSCs in in vivo modelsa

Preconditioning regimen Source of MSCs/species In vivo model/species Main findings of cell transplantation (versus non-preconditioned MSCs) Year of publication [reference]
Hypoxia BM-MSCs, human hind limb ischemia, mouse increased restoration of blood flow 2008 [75]
Hypoxia BM-MSCs, mouse myocardial infarction, mouse increased angiogenesis, reduced cell death and apoptosis of implanted cells 2008 [76]
Hypoxia AT-MSCs, human acute kidney injury, rat improved renal function, improved vascularization and histological injury 2014 [77]
Hypoxia AT-MSCs, mouse acute kidney injury, mouse ameliorated renal function, lower levels of pro-inflammatory cytokines 2016 [78]
Anoxia BM-MSCs, mouse myocardial infarction, mouse increased left ventricular ejection, reduced apoptotic cardiomyocytes 2006 [87]
Anoxia BM-MSCs, rat diabetic cardiomyopathy, rat increased capillary density, attenuated myocardial fibrosis, increased fractional shortening of diabetic heart 2008 [79]
3D spheroid culture BM-MSCs, human peritonitis, mouse better lung trafficking, more effective in suppressing inflammatory responses 2010 [88]
EGF BM-MSCs, mouse hind limb ischemia, mouse recovery of blood flow and angiogenesis 2010 [118]
PDGF-BB BM-MSCs, human myocardial infarction, mouse enhanced functional recovery 2015 [96]
TGF-β BM-MSCs, mouse acute myocardial injury, rat enhanced myocardial functional recovery 2010 [92]
GDNF AF-MSCs, human acute kidney injury, mouse ameliorated renal function and tubular injury, increased MSC homing to the tubulointerstitial compartment 2012 [93]
IGF-1 BM-MSCs, mouse acute kidney injury, mouse improved cell migration capacity, reduction in tubular necrosis, restored renal function 2013 [94]
FGF-2, IGF-1, BMP-2 BM-MSCs, rat myocardial infarction, rat smaller infarct size, better cardiac function, enhanced gap junction formation 2008 [91]
TNF-α AT-MSCs, human cutaneous wound-healing model, rat accelerated wound closure, angiogenesis, proliferation, improved wound repair 2011 [95]
SDF-1 BM-MSCs, rat myocardial infarction, rat reduction in infarct size and fibrosis, significant improvement in cardiac function, enhanced cell survival, engraftment, and vascular density 2008 [90]
Angiotensin-II BM-MSCs, rat myocardial infarction, rat better cardiac function, less cardiac fibrosis, smaller infarct size, higher expression of VEGF in ischemic myocardium 2015 [103]
Melatonin BM-MSCs, rat focal cerebral ischemia, rat reduced apoptosis, reduced brain infarction and improved neurobehavioral outcomes 2014 [104]
Melatonin BM-MSCs, rat acute kidney injury, rat increased MSC survival, proliferation of renal cells, accelerated renal recovery 2008 [105]
Oxytocin UC-MSCs, human myocardial infarction, rat increased ejection fraction, lower cardiac fibrosis and macrophage infiltration 2012 [119]
LPS BM-MSCs, mouse myocardial infarction, rat enhanced survival of engrafted MSCs and neovascularization, stimulated expression of VEGF, enhanced recovery of cardiac function 2009 [108]
TLR3 activation (Poly(I:C)) BM-MSCs, porcine cardiomyopathy, hamster improved cardiac function, decreased inflammatory cells and cytokines 2012 [120]
Hydrogen peroxide WJ-MSCs, human myocardial infarction, mouse improvement in left ventricular contractility, increased neovascularization and reduced myocardial fibrosis 2012 [121]
Deferoxamine BM-MSCs, rat streptozotocin-induced diabetes, rat increased homing of MSCs in pancreas 2013 [111]
a

We applied a PubMed search using the terms ‘preconditioning’ and ‘mesenchymal stem’. In addition, we only focus on preconditioning regimens tested in in vivo disease models and not simply in vitro studies with appropriate control animals, i.e., animals treated with non-preconditioned cells.

AF-MSCs = Amnion fluid-derived MSCs; AT-MSCs = adipose tissue-derived MSCs; BM-MSCs = bone marrow-derived MSCs; BMP = bone morphogenetic protein; EGF = epidermal growth factor; FGF = fibroblast growth factor; GDNF = glial cell-derived growth factor; IGF-1 = insulin-like growth factor-1; LPS = lipopolysaccharide; PDGF = platelet-derived growth factor; Poly(I:C) = polyinosinic:polycytidylic acid; SDF-1 = stromal cell-derived factor-1; ROS = reactive oxygen species; TGF-β = transforming growth factor-β; TLR = Toll-like receptor; TNF-α = tumor necrosis factor-α; VEGF = vascular endothelial growth factor; WJ-MSCs = Wharton's jelly-derived MSCs.